New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study
News
A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company announced in a press release. It is one of ... Read more